Pilot Studies for Development of an HIV Subtype Panel for Surveillance of Global Diversity


Autoria(s): Manak, Mark; Sina, Silvana; Anekella, Bharathi; Hewlett, Indira; Sanders-Buell, Eric; Ragupathy, Viswanath; Kim, Jerome; Vermeulen, Marion; Stramer, Susan L.; Sabino, Ester; Grabarczyk, Piotr; Michael, Nelson; Peel, Sheila; Garrett, Patricia; Tovanabutra, Sodsai; Busch, Michael P.; Schito, Marco
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

01/11/2013

01/11/2013

2012

Resumo

The continued global spread and evolution of HIV diversity pose significant challenges to diagnostics and vaccine strategies. NIAID partnered with the FDA, WRAIR, academia, and industry to form a Viral Panel Working Group to design and prepare a panel of well-characterized current and diverse HIV isolates. Plasma samples that had screened positive for HIV infection and had evidence of recently acquired infection were donated by blood centers in North and South America, Europe, and Africa. A total of 80 plasma samples were tested by quantitative nucleic acid tests, p24 antigen, EIA, and Western blot to assign a Fiebig stage indicative of approximate time from initial infection. Evaluation of viral load using FDA-cleared assays showed excellent concordance when subtype B virus was tested, but lower correlations for subtype C. Plasma samples were cocultivated with phytohemagglutinin (PHA)-stimulated peripheral blood mononuclear cells (PBMCs) from normal donors to generate 30 viral isolates (50-80% success rate for samples with viral load >10,000 copies/ml), which were then expanded to 10(7)-10(9) virus copies per ml. Analysis of env sequences showed that sequences derived from cultured PBMCs were not distinguishable from those obtained from the original plasma. The pilot collection includes 30 isolates representing subtypes B, C, B/F, CRF04_cpx, and CRF02_AG. These studies will serve as a basis for the development of a comprehensive panel of highly characterized viral isolates that reflects the current dynamic and complex HIV epidemic, and will be made available through the External Quality Assurance Program Oversight Laboratory (EQAPOL).

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272200800014C]

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-07-2-0067]

U.S. Department of Defense (DoD) [W81XWH-07-2-0067]

U.S. Department of Defense (DoD)

Identificador

AIDS RESEARCH AND HUMAN RETROVIRUSES, NEW ROCHELLE, v. 28, n. 6, supl., Part 3, pp. 594-606, JUN, 2012

0889-2229

http://www.producao.usp.br/handle/BDPI/37223

10.1089/aid.2011.0271

http://dx.doi.org/10.1089/aid.2011.0271

Idioma(s)

eng

Publicador

MARY ANN LIEBERT INC

NEW ROCHELLE

Relação

AIDS RESEARCH AND HUMAN RETROVIRUSES

Direitos

closedAccess

Copyright MARY ANN LIEBERT INC

Palavras-Chave #HUMAN-IMMUNODEFICIENCY-VIRUS #POLYMERASE CHAIN-REACTION #VIRAL-LOAD ASSAYS #DISEASE PROGRESSION #GENETIC-CHARACTERIZATION #TYPE-1 INFECTION #TRANSMISSION #RESISTANCE #PROTEASE #DYNAMICS #IMMUNOLOGY #INFECTIOUS DISEASES #VIROLOGY
Tipo

article

original article

publishedVersion